The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Mitochondrial-based Therapeutics Market Research Report 2024
Synopsis
Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.
Global Mitochondrial-based Therapeutics market is projected to reach US$ 651.3 million in 2029, increasing from US$ 379 million in 2022, with the CAGR of 7.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mitochondrial-based Therapeutics market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mitochondrial-based Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals
Segment by Type
Oral
Intravenous
Segment by Application
Mitochondrial Myopathy
Leber’s heredity Optic Neuropathy
Leigh Syndrome
Mitochondrial DNA Depletion Syndrome
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Mitochondrial-based Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Mitochondria are therefore vital for normal cellular function, including intracellular metabolic activities and signal transduction of various cellular pathways. They are involved in cellular ion homeostasis, oxidative stress, and apoptotic and necrotic cell death.
Global Mitochondrial-based Therapeutics market is projected to reach US$ 651.3 million in 2029, increasing from US$ 379 million in 2022, with the CAGR of 7.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mitochondrial-based Therapeutics market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mitochondrial-based Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Reneo Pharmaceutical
Pfizer Inc.
Norvartis AG
Takeda Pharmaceuticals
Amgen Inc.
NeuroVive Pharmaceutical AB
Entogene AG
Stealth Biotherapeutics
Ixchel Pharma
Reata Pharmaceuticals
Segment by Type
Oral
Intravenous
Segment by Application
Mitochondrial Myopathy
Leber’s heredity Optic Neuropathy
Leigh Syndrome
Mitochondrial DNA Depletion Syndrome
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Mitochondrial-based Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mitochondrial-based Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Intravenous
1.3 Market by Application
1.3.1 Global Mitochondrial-based Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Mitochondrial Myopathy
1.3.3 Leber’s heredity Optic Neuropathy
1.3.4 Leigh Syndrome
1.3.5 Mitochondrial DNA Depletion Syndrome
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mitochondrial-based Therapeutics Market Perspective (2018-2029)
2.2 Mitochondrial-based Therapeutics Growth Trends by Region
2.2.1 Global Mitochondrial-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Mitochondrial-based Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Mitochondrial-based Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Mitochondrial-based Therapeutics Market Dynamics
2.3.1 Mitochondrial-based Therapeutics Industry Trends
2.3.2 Mitochondrial-based Therapeutics Market Drivers
2.3.3 Mitochondrial-based Therapeutics Market Challenges
2.3.4 Mitochondrial-based Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mitochondrial-based Therapeutics Players by Revenue
3.1.1 Global Top Mitochondrial-based Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Mitochondrial-based Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Mitochondrial-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mitochondrial-based Therapeutics Revenue
3.4 Global Mitochondrial-based Therapeutics Market Concentration Ratio
3.4.1 Global Mitochondrial-based Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mitochondrial-based Therapeutics Revenue in 2022
3.5 Mitochondrial-based Therapeutics Key Players Head office and Area Served
3.6 Key Players Mitochondrial-based Therapeutics Product Solution and Service
3.7 Date of Enter into Mitochondrial-based Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Mitochondrial-based Therapeutics Breakdown Data by Type
4.1 Global Mitochondrial-based Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Type (2024-2029)
5 Mitochondrial-based Therapeutics Breakdown Data by Application
5.1 Global Mitochondrial-based Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Mitochondrial-based Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Mitochondrial-based Therapeutics Market Size (2018-2029)
6.2 North America Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
6.4 North America Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mitochondrial-based Therapeutics Market Size (2018-2029)
7.2 Europe Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
7.4 Europe Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mitochondrial-based Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Mitochondrial-based Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Mitochondrial-based Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mitochondrial-based Therapeutics Market Size (2018-2029)
9.2 Latin America Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mitochondrial-based Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Mitochondrial-based Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Mitochondrial-based Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Reneo Pharmaceutical
11.1.1 Reneo Pharmaceutical Company Detail
11.1.2 Reneo Pharmaceutical Business Overview
11.1.3 Reneo Pharmaceutical Mitochondrial-based Therapeutics Introduction
11.1.4 Reneo Pharmaceutical Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.1.5 Reneo Pharmaceutical Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Detail
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Mitochondrial-based Therapeutics Introduction
11.2.4 Pfizer Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.2.5 Pfizer Inc. Recent Development
11.3 Norvartis AG
11.3.1 Norvartis AG Company Detail
11.3.2 Norvartis AG Business Overview
11.3.3 Norvartis AG Mitochondrial-based Therapeutics Introduction
11.3.4 Norvartis AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.3.5 Norvartis AG Recent Development
11.4 Takeda Pharmaceuticals
11.4.1 Takeda Pharmaceuticals Company Detail
11.4.2 Takeda Pharmaceuticals Business Overview
11.4.3 Takeda Pharmaceuticals Mitochondrial-based Therapeutics Introduction
11.4.4 Takeda Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.4.5 Takeda Pharmaceuticals Recent Development
11.5 Amgen Inc.
11.5.1 Amgen Inc. Company Detail
11.5.2 Amgen Inc. Business Overview
11.5.3 Amgen Inc. Mitochondrial-based Therapeutics Introduction
11.5.4 Amgen Inc. Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.5.5 Amgen Inc. Recent Development
11.6 NeuroVive Pharmaceutical AB
11.6.1 NeuroVive Pharmaceutical AB Company Detail
11.6.2 NeuroVive Pharmaceutical AB Business Overview
11.6.3 NeuroVive Pharmaceutical AB Mitochondrial-based Therapeutics Introduction
11.6.4 NeuroVive Pharmaceutical AB Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.6.5 NeuroVive Pharmaceutical AB Recent Development
11.7 Entogene AG
11.7.1 Entogene AG Company Detail
11.7.2 Entogene AG Business Overview
11.7.3 Entogene AG Mitochondrial-based Therapeutics Introduction
11.7.4 Entogene AG Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.7.5 Entogene AG Recent Development
11.8 Stealth Biotherapeutics
11.8.1 Stealth Biotherapeutics Company Detail
11.8.2 Stealth Biotherapeutics Business Overview
11.8.3 Stealth Biotherapeutics Mitochondrial-based Therapeutics Introduction
11.8.4 Stealth Biotherapeutics Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.8.5 Stealth Biotherapeutics Recent Development
11.9 Ixchel Pharma
11.9.1 Ixchel Pharma Company Detail
11.9.2 Ixchel Pharma Business Overview
11.9.3 Ixchel Pharma Mitochondrial-based Therapeutics Introduction
11.9.4 Ixchel Pharma Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.9.5 Ixchel Pharma Recent Development
11.10 Reata Pharmaceuticals
11.10.1 Reata Pharmaceuticals Company Detail
11.10.2 Reata Pharmaceuticals Business Overview
11.10.3 Reata Pharmaceuticals Mitochondrial-based Therapeutics Introduction
11.10.4 Reata Pharmaceuticals Revenue in Mitochondrial-based Therapeutics Business (2018-2023)
11.10.5 Reata Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
